1
|
Sone T, Morikubo K, Miyahara M, Komiyama N, Shimizu K, Tsunoo H, Kino K. T Cell Epitopes in Japanese Cedar ( Cryptomeria japonica) Pollen Allergens: Choice of Major T Cell Epitopes in Cry j 1 and Cry j 2 Toward Design of the Peptide-Based Immunotherapeutics for the Management of Japanese Cedar Pollinosis. THE JOURNAL OF IMMUNOLOGY 1998. [DOI: 10.4049/jimmunol.161.1.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Japanese cedar pollinosis is caused by exposure to Japanese cedar (Cryptomeria japonica) pollen, of which two components, Cry j 1 and Cry j 2, are believed to be the major allergens. T cell lines specific to either Cry j 1 or rCry j 2 were reactive to various portions of each panel of overlapping peptides derived from Cry j 1 or Cry j 2. Two peptides, p211–225 and p108–120, from among six major T cell epitopes identified in Cry j 1 sequence, and three peptides, p182–200, p344–355, and p66–80, from among five in Cry j 2, were chosen to design an artificial polypeptide (named Cry-consensus) based on a difference among the types of the restriction molecules capable of presenting these peptides. After construction of a DNA encoding these peptides in order, Cry-consensus was expressed in Escherichia coli. Five of six T cell epitopes, except for Cry j 2 p344–355, in Cry-consensus were recognized by the T cell clones specific to each peptide. PBMC from allergic patients induced higher proliferation under stimulation from Cry-consensus than individual peptides. Eighty-eight percent of the PBMC (15 of 17) showed proliferation under the Cry-consensus stimulation. Thus, several major T cell epitopes from Cry j 1 and Cry j 2 can be chosen in the design of peptide-based immunotherapeutics for the management of Japanese cedar pollinosis in subjects having various types of HLA class II molecules.
Collapse
Affiliation(s)
- Toshio Sone
- Department of Pharmaceutical Research, Meiji Institute of Health Science, Odawara, Kanagawa, Japan
| | - Keiko Morikubo
- Department of Pharmaceutical Research, Meiji Institute of Health Science, Odawara, Kanagawa, Japan
| | - Michinori Miyahara
- Department of Pharmaceutical Research, Meiji Institute of Health Science, Odawara, Kanagawa, Japan
| | - Naoki Komiyama
- Department of Pharmaceutical Research, Meiji Institute of Health Science, Odawara, Kanagawa, Japan
| | - Kimiko Shimizu
- Department of Pharmaceutical Research, Meiji Institute of Health Science, Odawara, Kanagawa, Japan
| | - Hajime Tsunoo
- Department of Pharmaceutical Research, Meiji Institute of Health Science, Odawara, Kanagawa, Japan
| | - Kohsuke Kino
- Department of Pharmaceutical Research, Meiji Institute of Health Science, Odawara, Kanagawa, Japan
| |
Collapse
|